Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE